Organization
Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China
30 abstracts
Abstract
Impact of positive tumor-informed margin and TP53 mutations on surgical outcomes in esophageal squamous cell carcinoma.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Induction therapy with PD-1 antibody combined with platinum-based doublet chemotherapy for locally-advanced non-small cell lung cancer: A randomised controlled, open-label, phase 2 trial.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Shanghai Pulmonary Hospital, Shanghai, China, School of Medicine, Zhejiang University, Hangzhou, China, Tongji University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Neoadjuvant immunotherapy (PD-1) combined with chemotherapy for locally advanced thoracic esophageal carcinoma (EC): A single-arm, open-label, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, Tongji Medical College Huazhong University of Science and Technology, Huazhong University of Science and Technology Union Shenzhen Hospital, Wuhan, China,
Abstract
Tislelizumab combined with chemotherapy or radiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (TINES): A randomized, open, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The First Affiliated Hospital of Xi'an Jiaotong University, Xi 'an, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Envafolimab plus chemotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II study.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Tangdu Hospital, Air Force Military Medical University, Xi'an, China,
Abstract
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Updated data from a prospective, phase II trial.Org: Department of Biotherapy, Cancer Center, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University,
Abstract
Preoperative assessment in lung-limited metastatic patients with colorectal cancer: The Meta-Lung Score.Org: University Hospital and University of Cagliari, Division of Thoracic Surgery at “A. Businco Cancer Center”, Division of Thoracic Surgery, Brigham and Women's Hospital, Cardiovascular and Thoracic Department, Città della Salute e della Scienza,
Abstract
Tumor microenvironment-mediated immune profiles and efficacy of platinum doublet chemotherapy plus ICIs stratified by DLL3 expression in small cell lung cancer.Org: National Cancer Center Hospital East, Kashiwa, Japan, Division of Genome Biology, National Cancer Center Research Institute, Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, Department of Respiratory Medicine, NHO Iwakuni Clinical Center, Iwakuni, Japan,
Abstract
Neoadjuvant tislelizumab combined with chemoradiotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Single arm phase II study.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Science, Jinan, Shandong, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, Department of PET/CT Center, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
CRES3T: A single-arm confirmatory trial of S-1 plus cisplatin with concurrent radical-dose radiotherapy followed by surgery for superior sulcus tumor.Org: Juntendo University School of Medicine, Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan, Hiroshima University, National Cancer Center Hospital Japan East, Kashiwa, Japan, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX,
Abstract
A combinatorial model of plasma proteins and LDCT imaging and the diagnosis of pulmonary nodules.Org: Experimental Animal Center, Department of Pulmonary and Critical Care Medicine, Center of Respiratory Medicine, West China Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
EGFR assessment using next generation sequencing as a reflex testing on surgically resected non-squamous non-small cell lung carcinoma.Org: Laboratory of Clinical and Experimental Pathology, Pasteur Hospital, FHU OncoAge, Université Côte d’Azur, CHU Nice,
Abstract
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Shanghai Pulmonary Hospital, Shanghai, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, The Second Hospital Affiliated to Air Force Medical University, Qilu Pharmaceutical,
Abstract
Safety and efficacy of stereotactic body radiotherapy (SBRT) to oligoresidual sites combine with osimertinib in stage IV EGFR mutant NSCLC patients: A prospective pilot study.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Fujian Medical University Union Hospital, Department of PET/CT Center, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nosocomial Infection Control Branch, Fujian Medical University Union Hospital, Fuzhou, Fujian, China,
Abstract
Pretreatment radiomic biomarker for immunotherapy responder prediction in IB-IV stage NSCLC: A multi-center retrospective study.Org: Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China, Southern Medical University, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma,
Abstract
Deep learning algorithm for automatic prediction of visceral pleural invasion of lung cancer based on surgical video.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Peking University People's Hospital, School of Engineering Medicine，Beihang University,
Abstract
Neoadjuvant tislelizumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC): Interim analysis of a phase 2 study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Peking Union Medical College Hospital,CAMS & PUMC, Department of Gastroenterology and Urology, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy,
Abstract
Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non–small-cell lung cancer after stereotactic body radiation therapy.Org: Department of Radiation Medicine and Applied Sciences, Roswell Park Comprehensive Cancer Center, Cornell University, University at Buffalo Jacobs School of Medicine and Biomedical Sciences, Roswell Park Cancer Institute,
Abstract
Personalized circulating tumor DNA (ctDNA) analysis in predicting residual disease after neoadjuvant chemoradiotherapy (nCRT) for esophageal squamous cell carcinoma (ESCC).Org: Shanghai Chest Hospital, Jiaotong University, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China,
Abstract
Pembrolizumab and ramucirumab neoadjuvant therapy for PD-L1-positive stage IB-IIIA lung cancer (EAST ENERGY).Org: Department of Thoraci surgery, National Cancer Center Hospital East, Kashiwa, Japan, Division of Thoracic and Thyroid Surgery, Tokyo Medical University, Department of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan,
Abstract
Clinical characteristics and treatment outcome of patients with advanced non-small-cell lung cancer (NSCLC) and FGFR fusions.Org: University of Cologne, University Hospital Cologne Center for Integrated Oncology, Institute for Pathology, Department of Translational Genomics, Network Genomic Medicine,
Abstract
Multi-omics analysis to reveal the change of peripheral blood TCR repertoire and tumor burden during neoadjuvant chemotherapy combined with sequential PD-1 blockade for patients with non-small cell lung cancers: A single-center, single-arm phase 2 trial.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Chinese PLA General Hospital, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy, School of Medicine Nankai University,
Abstract
Class II and class III BRAF mutations in patients with advanced non-small cell lung cancer (NSCLC): Clinical characteristics, mutation patterns, and survival outcomes.Org: Network Genomic Medicine, University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), University of Cologne,
Abstract
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy in patients with unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): A single-arm, phase Ⅱ trial.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Gastrointestinal Surgery Center, Department of Gastroenterology and Urology, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China,
Abstract
Influence of high COL19A1 expression on the effectiveness of neoadjuvant immunotherapy plus chemotherapy and long-term survival in patients with esophageal squamous cell carcinoma.Org: Guangdong Provincial People's Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China,
Abstract
Role of synthetic lethal mutations for the immune response: Exploratory studies of two non-small cell lung cancer cohorts and two pan-cancer cohorts.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China, The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd., 3D Medicine Inc.,
Abstract
Radiation-sensitive genetic prognostic model to identify individuals at risk for radiation resistance in head and neck squamous cell carcinoma.Org: Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China, Cancer Hospital of Nanchang University, Jiangxi Key Laboratory of Translational Cancer Research, Jiangxi Cancer Hospital of Nanchang University, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China,
Abstract
Characteristics and trends of globally registered malignant pleural mesothelioma clinical trials in the past 27 years.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangdong Pharmaceutical University, Guangzhou, China, Guangdong Provincial People's Hospital,
Abstract
The impact of 4R Oncology Model on patient self management and satisfaction in lung versus breast cancer.Org: Center for Business Models on Healthcare, Northwestern University Feinberg School of Medicine, Kaiser Permanente Oakland Medical Center, Division of Research Services, Kaiser Permanente Northern California,
Abstract
A 9-gene signature in circulating tumor DNA based on molecular residual disease detection to predict recurrence of resectable non–small-cell lung cancer.Org: Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Department of Thoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, Guangzhou, China, Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., Nanjing, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Nanfang Hospital, Southern Medical University, Guangzhou, China, Berry Oncology Corporation,